Measuring productivity loss in early relapsing-remitting multiple sclerosis.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 13 10 2021
accepted: 08 11 2021
entrez: 26 2 2022
pubmed: 27 2 2022
medline: 3 3 2022
Statut: ppublish

Résumé

Multiple sclerosis is one of the most common causes of neurological disability in young adults with major consequences for their autonomy and capacity to maintain employment. The aim of this study was to assess the impact on work productivity in early-stage relapsing-remitting multiple sclerosis (RRMS). A multicenter, non-interventional study was conducted. Adult patients with a diagnosis of RRMS, a disease duration ≤ 3 years, and an Expanded Disability Status Scale (EDSS) score of 0-5.5 were included. Absenteeism, presenteeism, and unpaid work loss due to RRMS were measured using the Valuation of Lost Productivity (VOLP) questionnaire. The EDSS, SymptoMScreen, 5-item Modified Fatigue Impact Scale, Hospital Anxiety and Depression Scale, Symbol Digit Modalities Test, and Multiple Sclerosis Work Difficulties Questionnaire were used to gather information on disability, patients' perception of symptom severity, fatigue, mood/anxiety, cognition, and problems in the workplace, respectively. Associations between the VOLP and clinical and work outcomes were analyzed using Spearman's rank correlations. A total of 189 patients were included. Mean age (SD) was 36.1 ± 9.4 years and 71.4% were female. Mean disease duration was 1.2 ± 0.8 years. Median EDSS score was 1.0 (IQR 0, 2.0). One hundred thirty patients (68.8%) were working for pay or self-employed. Fifty-three patients (40.8%) reported absence from work in the past 3 months with an average of 14.3 absent workdays. Their health problems resulted in the loss of 3.4% of their actual work time in the past 7 days. Thirty patients got help (11.8 h) with their unpaid work activities in the past 7 days. Absenteeism was significantly correlated with anxiety and depression (rho=0.298 and 0.291, p<0.001), fatigue (rho=0.214, p = 0.014), and symptom severity (rho=0.213, p = 0.015). Presenteeism was significantly correlated with fatigue (rho=0.375, p<0.001), symptom severity (rho=0.373, p<0.001), depression (rho=0.263, p = 0.008), and disability (rho=0.215, p = 0.031). Productivity loss even in a RRMS population with short disease duration stresses the need for more efficient treatment control of disease activity from earlier stages.

Sections du résumé

BACKGROUND BACKGROUND
Multiple sclerosis is one of the most common causes of neurological disability in young adults with major consequences for their autonomy and capacity to maintain employment.
OBJECTIVE OBJECTIVE
The aim of this study was to assess the impact on work productivity in early-stage relapsing-remitting multiple sclerosis (RRMS).
METHODS METHODS
A multicenter, non-interventional study was conducted. Adult patients with a diagnosis of RRMS, a disease duration ≤ 3 years, and an Expanded Disability Status Scale (EDSS) score of 0-5.5 were included. Absenteeism, presenteeism, and unpaid work loss due to RRMS were measured using the Valuation of Lost Productivity (VOLP) questionnaire. The EDSS, SymptoMScreen, 5-item Modified Fatigue Impact Scale, Hospital Anxiety and Depression Scale, Symbol Digit Modalities Test, and Multiple Sclerosis Work Difficulties Questionnaire were used to gather information on disability, patients' perception of symptom severity, fatigue, mood/anxiety, cognition, and problems in the workplace, respectively. Associations between the VOLP and clinical and work outcomes were analyzed using Spearman's rank correlations.
RESULTS RESULTS
A total of 189 patients were included. Mean age (SD) was 36.1 ± 9.4 years and 71.4% were female. Mean disease duration was 1.2 ± 0.8 years. Median EDSS score was 1.0 (IQR 0, 2.0). One hundred thirty patients (68.8%) were working for pay or self-employed. Fifty-three patients (40.8%) reported absence from work in the past 3 months with an average of 14.3 absent workdays. Their health problems resulted in the loss of 3.4% of their actual work time in the past 7 days. Thirty patients got help (11.8 h) with their unpaid work activities in the past 7 days. Absenteeism was significantly correlated with anxiety and depression (rho=0.298 and 0.291, p<0.001), fatigue (rho=0.214, p = 0.014), and symptom severity (rho=0.213, p = 0.015). Presenteeism was significantly correlated with fatigue (rho=0.375, p<0.001), symptom severity (rho=0.373, p<0.001), depression (rho=0.263, p = 0.008), and disability (rho=0.215, p = 0.031).
CONCLUSIONS CONCLUSIONS
Productivity loss even in a RRMS population with short disease duration stresses the need for more efficient treatment control of disease activity from earlier stages.

Identifiants

pubmed: 35216781
pii: S2211-0348(21)00665-9
doi: 10.1016/j.msard.2021.103398
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

103398

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Susana Sainz de la Maza (S)

Department of Neurology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Jorge Maurino (J)

Medical Department, Roche Farma, Madrid, Spain. Electronic address: jorge.maurino@roche.com.

Mónica Borges (M)

Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain.

Jesús Martín-Martínez (J)

Department of Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain.

Javier Sotoca (J)

Department of Neurology, Hospital Universitari MútuaTerrassa, Terrassa, Barcelona, Spain.

Ana Alonso (A)

Department of Neurology, Hospital Regional Universitario de Málaga, Málaga, Spain.

Ana B Caminero (AB)

Department of Neurology, Complejo Asistencial de Ávila, Ávila, Spain.

Laura Borrega (L)

Department of Neurology, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain.

José L Sánchez-Menoyo (JL)

Department of Neurology, Hospital de Galdakao-Usansolo, Galdakao, Spain.

Francisco J Barrero-Hernández (FJ)

Department of Neurology, Hospital Universitario Clínico San Cecilio, Granada, Spain.

Carmen Calles (C)

Department of Neurology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.

Luis Brieva (L)

Department of Neurology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.

Maria R Blasco (MR)

Department of Neurology, Hospital Universitario Puerta de Hierro, Madrid, Spain.

Julio Dotor García-Soto (JD)

Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain.

María Del Campo-Amigo (MD)

Department of Neurology, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.

Laura Navarro-Cantó (L)

Department of Neurology, Hospital General Universitario de Elche, Elche, Spain.

Eduardo Agüera (E)

Department of Neurology, Hospital Universitario Reina Sofía, Córdoba, Spain.

Moisés Garcés (M)

Department of Neurology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

Olga Carmona (O)

Department of Neurology, Fundació Salut Empordà, Figueres, Spain.

Laura Gabaldón-Torres (L)

Department of Neurology, Hospital Francesc de Borja, Gandía, Spain.

Lucía Forero (L)

Department of Neurology, Hospital Universitario Puerta del Mar, Cádiz, Spain.

Mariona Hervás (M)

Department of Neurology, Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain.

Lucía Ruiz de Alda (LR)

Health Economics and Outcomes Research Unit, Roche Farma, Madrid, Spain.

Rocío Gómez-Ballesteros (R)

Medical Department, Roche Farma, Madrid, Spain.

Tamara Castillo-Triviño (T)

Department of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH